Nasdaq:US$15.14 (-0.26) | HKEX:HK$23.80 (+0.04) | AIM:£2.28 (+0.08)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 16 Oct 2010

ISSX 2011: Preclinical assessment of the absorption, distribution, metabolism and excretion of HMPL-013 (fruquintinib), a novel potent and specific VEGFR inhibitor